3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call

Competition with AbbVie and Merck is important, but hepatitis C shouldn't be your sole focus.

Jul 22, 2014 at 5:01PM

Gilead Sciences (NASDAQ:GILD) plans to release second quarter financials on Wednesday. Here are three things investors should pay attention to during the conference call.

1. How sustainable are hepatitis C sales?
This is literally the multi-billion dollar question. Sovaldi sales north of $3 billion would be nice. If it can hit $3.5 billion, investors will do a little dance for sure.

But while the higher the sales the better, one quarter of sales doesn't tell you how much Gilead is worth. The biotech's long-term value is ultimately determined by sales of Sovaldi-containing cocktails over years, not quarters.

A cocktail containing Sovaldi and ledipasvir is under review at the FDA and should be approved by the end of the year. Doctors may wait for that combination, but investors shouldn't freak out if sales of Sovaldi alone fall next quarter. Gilead should be able to capture most of those delayed sales when patients take Sovaldi-ledipasvir, presumably at a higher price.

AbbVie's (NYSE:ABBV) all-oral cocktail should be approved just after Sovaldi-ledipasvir, but Gilead looks like it has AbbVie beat on convenience, requiring fewer pills per day. Look for discussion of potential price wars during the conference call.

The bigger threat could come from Merck (NYSE:MRK), which recently announced plans to acquire Idenix Pharmaceuticals. Merck is further behind Gilead an AbbVie, but its cocktail could potentially supplant Sovaldi-ledipasvir if it works just as well but allows patients to take the drug for a shorter time.

2. Oh, about those HIV sales
Remember when Gilead was an HIV drug company?

It still is.

When a single drug is producing revenue of $3 billion in one quarter, it's easy to forget about its other drugs, but the combined sales of Atripla, Truvada and the rest of Gilead's HIV franchise should still top $2 billion this quarter, having almost as much impact on revenue and profit as Sovaldi will.

The HIV drug to watch is Stribild, a quad pill developed internally by Gilead. Top selling HIV drug Atripla contains a medication developed by Bristol-Myers Squibb, so Gilead has to share Atripla revenue with the pharma. In the first quarter, Stribild sales were up 134% year over year, while Atripla's sales dropped 11% year over year. Stribild is approaching blockbuster status, but sales are still less than a third of Atripla, so there's more work to be done .

3. So what are you going to do with all that cash?
Not only does having $3 billion in Sovaldi sales essentially double Gilead's revenue, but profits increase even further because every $1 billion in Sovaldi sales improves non-GAAP product gross margins and non-GAAP effective tax rate by 0.75% to 1%.

In May, Gilead announced a $5 billion share repurchase plan. And that was on top of the $2.9 billion it still had left on the one set up in 2011 . Given the uncertainty about how long the Sovaldi-sales will last, a share buyback is more appropriate than starting a dividend that might not be sustainable.

But is buying back shares the best use of Gilead's capital? Are there really no better deals in biotech land than buying shares of Gilead?

I'd like to see Gilead buy an oncology company with a drug or two already on the market. Gilead has idelalisib under review for a couple of a couple different blood cancers and a pipeline of other oncology drugs, but no experience selling cancer drugs. Combining idelalisib with some other cancer drugs could also help with margins if there was sales force overlap.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers